Lymphoma by Site — Trials

Lymphoma by Site — Trials · CancerIndex

Clinical trials

Registered studies

900 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 250
Recruiting: 134
Ph III recruiting: 7
Growth YoY: +20%
Industry share: 17%
Top sponsor: National Cancer Institute (NCI)
Termination share: 33.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (130)

clinicaltrialsPublishedShowing 301–307 of 307 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05347641	Penpulimab Combined With RMA Treatment of Primary Diagnosis of Primary Central Nervous System Lymphoma	not yet recruiting	Phase 2	23	The First Affiliated Hospital with Nanjing Medical UniversityOTHER	0	Apr 26, 2022	clinicaltrials
NCT05260619	Lenalidomide Maintenance Treatment in Patients With Primary Central Nervous System Lymphoma(PCNSL-LEM)	recruiting	Phase 2	28	Seoul National University Bundang HospitalOTHER